Literature DB >> 33307545

Membrane vesicles nanotheranostic systems: sources, engineering methods, and challenges.

Weidong Nie1, Guanghao Wu2, Haizheng Zhong1, Hai-Yan Xie2.   

Abstract

Extracellular vesicles (EVs) are cell secretory native components with long-circulation, good biocompatibility, and physiologic barriers cross ability. EVs derived from different donor cells inherit varying characteristics and functions from their original cells and are favorable to serve as vectors for diagnosing and treating various diseases. However, EVs nanotheranostics are still in their infancy because of their limited accumulation at lesion sites and compromised therapy efficiency. Hence, engineering modification of EVs is usually needed to further enhance their stability, biological activity, and lesion-targeting capacity. Herein, we overview the characteristics of EVs from different sources, as well as the latest developments of surface engineering and cargo loading methods. We also focus especially on advances in EVs-based disease theranostics. At the end of the review, we predict the obstacles and prospects of the future clinical application of EVs.

Entities:  

Mesh:

Year:  2021        PMID: 33307545     DOI: 10.1088/1748-605X/abd2c8

Source DB:  PubMed          Journal:  Biomed Mater        ISSN: 1748-6041            Impact factor:   3.715


  3 in total

Review 1.  Direct Modification of Extracellular Vesicles and Its Applications for Cancer Therapy: A Mini-Review.

Authors:  Wenbin Nan; Chao Zhang; Hao Wang; Hongli Chen; Shenglu Ji
Journal:  Front Chem       Date:  2022-05-11       Impact factor: 5.545

Review 2.  Application of engineered extracellular vesicles for targeted tumor therapy.

Authors:  Fusheng Zhang; Jinshuai Guo; Zhenghou Zhang; Meiqi Duan; Guang Wang; Yiping Qian; Haiying Zhao; Zhi Yang; Xiaofeng Jiang
Journal:  J Biomed Sci       Date:  2022-02-21       Impact factor: 8.410

3.  Tumor suppressive role of microRNA-139-5p in bone marrow mesenchymal stem cells-derived extracellular vesicles in bladder cancer through regulation of the KIF3A/p21 axis.

Authors:  Ying Xiang; Dong Lv; Tao Song; Chao Niu; Ying Wang
Journal:  Cell Death Dis       Date:  2022-07-12       Impact factor: 9.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.